Mauricio Waintrub, MD
Internal Medicine · Aurora, CONPI 1417900200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Amgen$986
- Gilead$638
- Johnson & Johnson$548
- Novartis$546
- plus $4K from 42 others
Across 124 payments — averaging $10,243 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$906K
- GSK$123K
- Modernatx, Inc.$91K
- AstraZeneca$87K
- Organon$20K
- AbbVie$15K
- plus $30K from 3 others
What the payments were for
- Food & beverage$9,464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,464 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 143 | $153,170 |
| OzempicSemaglutide | 98 | $150,268 |
| EliquisApixaban | 300 | $130,298 |
| TrulicityDulaglutide | 28 | $53,010 |
| XareltoRivaroxaban | 67 | $47,939 |
| Xeljanz XrTofacitinib Citrate | 12 | $43,166 |
| MounjaroTirzepatide | 23 | $42,832 |
| JanuviaSitagliptin Phosphate | 38 | $39,529 |
| JardianceEmpagliflozin | 62 | $36,351 |
| Spiriva HandihalerTiotropium Bromide | 29 | $18,575 |
| EntrestoSacubitril/Valsartan | 17 | $17,585 |
| MyrbetriqMirabegron | 38 | $13,005 |
| Gabapentin | 444 | $12,664 |
| LinzessLinaclotide | 15 | $12,514 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $12,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $1,638 | $158,723165 claims |
| Novo NordiskOzempic | $330 | $150,26898 claims |
| PfizerEliquis | $263 | $130,298300 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $291 | $95,84351 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $347 | $54,32894 claims |
| MerckJanuvia, Dulera | $272 | $49,18565 claims |
| Johnson & JohnsonXarelto | $548 | $47,93967 claims |
| NovartisEntresto | $546 | $17,58517 claims |
| GSKBreo Ellipta, Incruse Ellipta | $194 | $15,48928 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $13,00538 claims |
| AbbVieLinzess | $1,002 | $12,51415 claims |
| Sanofi-aventis U.S. LLCLantus | $137 | $3,34236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Aurora
- Kristine KuhnAurora$61K
- Paul Menard-KatcherAurora$32K
- Cherry DelosreyesAurora$15K
- Shabana JiwaniAurora$10K
- Shahzaib NabiAurora$10K
- Javier WaksmanAurora$7K
- Kelsey FlintAurora$6K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.